npj Parkinsons Disease

npj Parkinson's Disease is a peer-reviewed open access journal published by Nature Portfolio since 2015 under the eISSN 2373-8057, covering basic, translational and clinical research on Parkinson's disease and related movement disorders, with a 2025 Journal Impact Factor of 8.5 and a first quartile rank of 20 of 330 in neurosciences《帕金森病》（npj Parkinson's Disease）是自然出版集团（Nature Portfolio）自 2015 年起出版的同行评审开放获取期刊，电子刊号 2373-8057，覆盖帕金森病及相关运动障碍的基础、转化与临床研究，2025 年影响因子为 8.5，在神经科学类 330 种期刊中列第 20 位、居第一四分位。

Scope

• The journal is part of the Nature Partner Journals series launched in partnership with the Michael J Fox Foundation for Parkinson's Research, and it publishes original research, reviews, perspectives and case reports across the Parkinson's disease field该刊是自然合作期刊系列之一，与米高福克斯帕金森研究基金会（Michael J Fox Foundation）合作创办，刊载帕金森病领域的原创研究、综述、观点与病例报告。
• It covers basic research on disease mechanisms including alpha-synuclein biology, mitochondrial dysfunction, neuroinflammation, genetic and environmental risk factors, and the pathophysiology of dopaminergic and non-dopaminergic systems该刊覆盖疾病机制的基础研究，包括α-突触核蛋白生物学、线粒体功能障碍、神经炎症、遗传与环境风险因素，以及多巴胺能与非多巴胺能系统的病理生理。
• The journal addresses translational and clinical research including biomarker discovery and validation, neuroimaging, disease subtyping, clinical trials, epidemiology, and the development and evaluation of therapeutic and neuroprotective strategies该刊涉及转化与临床研究，包括生物标志物发现与验证、神经影像、疾病亚型、临床试验、流行病学，以及治疗与神经保护策略的开发与评价。
• It also covers deep brain stimulation and device-based therapies, digital biomarkers and remote monitoring, patient-reported outcomes, and the non-motor symptoms and quality of life of people living with Parkinson's disease该刊亦覆盖脑深部刺激与器械治疗、数字生物标志物与远程监测、患者报告结局，以及帕金森病患者的非运动症状与生活质量。
• As an open access journal it applies a Creative Commons attribution licence to accepted articles and levies an article processing charge on the corresponding author, and it operates single-blind peer review作为开放获取期刊，该刊对录用文章采用知识共享署名许可，向通讯作者收取文章处理费，实行单盲同行评审。
• In the 2025 Journal Citation Reports it ranks 20 of 330 titles in neurosciences with a 94.1 percentile and its five year indicator remains in the first quartile在 2025 年版期刊引证报告中，该刊在神经科学类 330 种期刊中列第 20 位、百分位 94.1，五年指标同样位于第一四分位。

History

• The journal was launched in 2015 as part of the Nature Partner Journals series, a collaboration between Nature Portfolio and external partners, with the Michael J Fox Foundation for Parkinson's Research as the founding partner该刊于 2015 年作为自然合作期刊系列的一部分创刊，该系列由自然出版集团与外部伙伴合作创办，米高福克斯帕金森研究基金会为创始伙伴。
• It has been published as a fully open access title since its first volume, applying a Creative Commons attribution licence to accepted articles, aligning with the open access mandates of biomedical research funders该刊自第一卷起即为完全开放获取期刊，对录用文章采用知识共享署名许可，契合生物医学研究资助机构的开放获取要求。
• The Journal Impact Factor moved from 8.651 in 2021 to 9.304 in 2022, then to 8.2 in 2024 and to 8.5 in 2025, maintaining first quartile standing in neurosciences throughout该刊影响因子由 2021 年的 8.651 升至 2022 年的 9.304，再降至 2024 年的 8.2 与 2025 年的 8.5，始终居神经科学类第一四分位。
• The journal has progressively expanded its content to address digital biomarkers, artificial intelligence for diagnosis and monitoring, and the long non-coding RNA and gut microbiome dimensions of Parkinson's disease该刊逐步扩展内容，纳入数字生物标志物、面向诊断与监测的人工智能，以及帕金森病的长非编码核糖核酸与肠道菌群维度。
• The publisher carries the journal on nature.com and the digital object identifier prefix of its articles is 10.1038, shared with other Nature Portfolio titles出版方将该刊载于（nature.com），其文章的数字对象唯一标识符前缀为（10.1038），与自然出版集团其他期刊一致。

Editors

• The journal is led by an editor-in-chief supported by an editorial board whose members are drawn from neurology, neuroscience, movement disorder centres and translational research institutes across the world该刊由一位主编带领，配以由世界各地神经病学、神经科学、运动障碍中心与转化研究机构的学者组成的编委会。
• The editorial team includes associate editors responsible for subject areas such as disease mechanisms, biomarkers, clinical trials, neuroimaging and therapeutic development, reflecting the translational scope of the journal编辑团队设有副编辑，分别负责疾病机制、生物标志物、临床试验、神经影像与治疗开发等方向，对应刊物的转化定位。
• Editorial handling follows the Nature Portfolio editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托自然出版集团的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is single-blind and the journal maintains the Nature Portfolio standards on reviewer recruitment, conflict of interest management, data sharing and editorial independence同行评审采用单盲方式，该刊遵循自然出版集团在审稿人遴选、利益冲突管理、数据共享与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at nature.com and updated as new members join or existing members step down编委名单在（nature.com）期刊页公布，并随成员增减而更新。